The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 5 , Pages 1014-1021 , May 2008

Prevention of local tumor growth with paclitaxel-loaded microspheres

  • Solomon M. Azouz, MS

      Affiliations

    • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Joseph Walpole, BS

      Affiliations

    • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Sepideh Amirifeli, MD

      Affiliations

    • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Kendra N. Taylor, PhD

      Affiliations

    • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Mark W. Grinstaff, PhD

      Affiliations

    • Departments of Biomedical Engineering and Chemistry, Boston University, Boston, Mass
    • ,
  • Yolonda L. Colson, MD, PhD

      Affiliations

    • Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationAddress for reprints: Yolonda L. Colson, MD, PhD, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

Received 24 October 2007 ,Revised 18 December 2007 ,Accepted 22 December 2007.

References 

  1. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615–623
  2. Landreneau RJ, Sugarbaker DJ, Mack MJ, Hazelrigg SR, Luketich JD, Fetterman L, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:691–700
  3. Miller JI, Hatcher CR. Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. Ann Thorac Surg. 1987;44:340–343
  4. Lee W, Daly BD, DiPetrillo TA, Morelli DM, Neuschatz AC, Morr J, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I125 brachytherapy seeds. Ann Thorac Surg. 2003;75:237–243
  5. Detterbeck FC, Rivera PM, Socinski MA, Rosenman JC. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing physician. Philadelphia: W. B. Saunders Company; 2001;177-90
  6. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120–129
  7. Edlund U, Albertsson A. Degradable microspheres for controlled drug delivery. Adv Polymer Sci. 2001;157:67
  8. Wang YM, Sato H, Adachi I, Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem Pharm Bull (Tokyo). 1996;44:1935–1940
  9. Ormerod MG. Flow cytometry: a practical approach. 2nd ed.. Oxford: IRL Press; 1994;
  10. Alam M, Wang J, Coffey J, Qadri S, O'Donnell A, Aherne T, et al. Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non–small cell lung cancer cell lines. Ann Surg Oncol. 2007;14:2678–2684
  11. Qadri SSA, Wang J-H, Coffey JC, Alam M, O'Donnell A, Aherne T, et al. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg. 2005;79:990–995
  12. Thomas P, Rubinstein L. Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1990;49:242–247
  13. Keenan RJ, Landreneau RJ, Maley RH, Singh D, Macherey R, Bartley S, et al. Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg. 2004;78:228–233
  14. El-Sherif A. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14:2400–2405
  15. Wu XS, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation. J Biomater Sci. 2001;12:21–34
  16. Xie M, Zhou L, Hu T, Yao M. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts. Anticancer Drugs. 2007;18:459–466
  17. Harper E, Dang W, Lapidus RG, Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 1999;5:4242–4248
  18. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83:273–286
  19. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs. 1996;7:78–86
  20. Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, et al. Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr. 1993;(15):39–46
  21. Kraeber-Bodere F, Sai-Maurel C, Campion L, Faivre-Chauvet A, Mirallie E, Cherel M, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;1:267–274

PII: S0022-5223(08)00032-9

doi: 10.1016/j.jtcvs.2007.12.011

The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 5 , Pages 1014-1021 , May 2008

Article Tools

* Image Usage & Resolution